Document:

Exhibit 10.8

 

FORM OF SUBSCRIPTION AGREEMENT

 

Bionik Laboratories Inc.

10 Dundas St. E. Office AMC-B202

Toronto, ON M5B 2G9

 

Ladies and Gentlemen:

 

1.          Subscription.
The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from
Bionik Laboratories Inc., a [_____] corporation (“Pubco”), the number of Units (the “Units”)
set forth on the signature page hereof at a purchase price of $0.80 per Unit. Each Unit consists of (i) one share of common stock,
par value $0.001 per share, of Pubco (the “Common Stock”), and (ii) warrant to purchase one share of Common
Stock (the “Warrant Shares”) for a four (4) year period from the first closing of the Offering (as defined below)
at an initial exercise price of $1.40 per share (each a “Warrant” and collectively, the “Warrants”).
The Units are being offered in connection with a share exchange, merger or similar agreement with Pubco or a wholly owned subsidiary
of Pubco, on the one hand, and Bionik Laboratories Inc., a corporation organized under the Canada Business Corporations Act (the
“Company”), on the other hand, pursuant to which the Company will merge with or otherwise be acquired, directly
or indirectly, by Pubco (the “Reverse Merger”). Unless the context provides to the contrary, reference in this
Subscription Agreement to the “Company” as of and subsequent to the closing of the Minimum Amount (as defined below),
means Pubco assuming the consummation of the Reverse Merger.

 

This subscription is submitted to the Purchaser
in accordance with and subject to the terms and conditions described in this Subscription Agreement and the Confidential Private
Placement Memorandum of the Company, dated July 23, 2014, as amended or supplemented from time to time, including all attachments,
schedules and exhibits thereto (the “Memorandum”), relating to the private placement offering (the “Offering”)
by the Company of a minimum of ten million Units ($8,000,000) (the “Minimum Amount”) and a maximum of sixteen
million Units ($12,800,000) (the “Maximum Amount”). The Units are being offered by the Company on an exclusive
basis through Merriman Capital, Inc. (the “Placement Agent”) and such agents and/or sub-placement agents as
may be engaged by the Placement Agent on a “reasonable best efforts, all or none” basis with respect to the Minimum
Amount and on a “reasonable best efforts” basis with respect to all Units in excess of the Minimum Amount. The minimum
purchase is 125,000 Units ($100,000), although the Company and the Placement Agent may, in their discretion, accept subscriptions
for a lesser number of Units.

 

The terms of the Offering are more completely
described in the Memorandum and such terms are incorporated by reference herein in their entirety.

 

2.          Payment.
The Purchaser encloses herewith a check payable to, or will immediately make a wire transfer payment to, “Signature Bank,
as Escrow Agent for Bionik Laboratories Inc.” in the full amount of the purchase price of the Units being subscribed for.
Wire transfer instructions are set forth on the instruction page accompanying this Subscription Agreement. Such funds will be held
for the Purchaser’s benefit, and will be returned promptly, without interest or offset if the Purchaser’s subscription
is not accepted by the Company for any reason or no reason, the Offering is terminated pursuant to its terms by the Company or
the Placement Agent prior to the First Closing (as hereinafter defined), or the Minimum Amount is not sold or the Reverse Merger
is not consummated.

 

    	 

    	 

    

 

3.          Deposit
of Funds. All payments made as provided in Section 2 hereof shall be deposited by the Company or the Placement Agent as soon
as practicable after receipt thereof with Signature Bank (the “Escrow Agent”), in a non-interest-bearing escrow
account (the “Escrow Account”) until the earliest to occur of: (a) the closing of the sale of the Units being
purchased pursuant to this Subscription Agreement in accordance with the Offering terms, (b) the rejection of such subscription
and (c) the termination of the Offering by the Company or the Placement Agent. The Company and the Placement Agent may continue
to offer and sell the Units and conduct additional closings for the sale of additional Units after the initial closing of the Offering
(“First Closing”) and until the termination of the Offering. In the event that the Company does not effect a
closing of the Offering on or before September 30, 2014 (the “Initial Offering Period”), which period may be
extended by the Company and the Placement Agent, in their mutual discretion to a date no later than a maximum of two 30 day extensions
(the “Termination Date”, with this additional period, together with the Initial Offering Period, being referred
to herein as the “Offering Period”), the Company will refund all subscription funds, without deduction, offset
and/or interest accrued thereon, and will return the subscription documents to each Purchaser. If the Company rejects a subscription,
either in whole or in part (which decision is in their sole discretion), the rejected subscription funds or the rejected portion
thereof will be returned promptly to such Purchaser without interest accrued thereon. 

 

4.          Acceptance
of Subscription. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept
or reject this or any other subscription for Units, in whole or in part, and for any reason or no reason, notwithstanding prior
receipt by the Purchaser of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the
Company shall execute and deliver to the Purchaser an executed copy of this Subscription Agreement. If this subscription is rejected
in whole, the Offering is terminated, or the Minimum Amount is not sold (or the Reverse Merger is not consummated) within the Offering
Period, all funds received from the Purchaser will be returned without interest or offset, and this Subscription Agreement shall
thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion of this
subscription will be returned without interest or offset, and this Subscription Agreement will continue in full force and effect
to the extent this subscription was accepted.

 

5.          Representations
and Warranties of the Purchaser. The Purchaser hereby acknowledges, represents, warrants and agrees to and with the Company
as follows (it being specifically acknowledged and agreed that the Placement Agent is and shall be a third party beneficiary of
the following):

 

(a)          The
Purchaser is aware that an investment in the Units involves a significant degree of risk, involving a number of very significant
risks and has carefully read and considered the matters set forth in the Memorandum, including but not limited to under the caption
“Risk Factors” in the Memorandum.

 

(b)          None
of the securities comprising the Units, including the Common Stock and the Warrants offered pursuant to the Memorandum, or the
Warrant Shares, are registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state
securities laws. The Purchaser understands that the offering and sale of the Units (including the Common Stock and the Warrants)
and the Warrant Shares are intended to be exempt from registration under the Securities Act, by virtue of Section 4(a)(2) thereof
and the provisions of Regulation D promulgated thereunder (“Regulation D”), based, in part, upon the representations,
warranties and agreements of the Purchaser contained in this Subscription Agreement.

 

(c)          The
Purchaser meets the requirements of at least one of the suitability standards for an “accredited investor” as that
term is defined in Regulation D and as set forth on the Accredited Investor Certification contained herein.

 

    	 

    	 

    

 

(d)         Prior
to the execution of this Subscription Agreement, the Purchaser and the Purchaser’s attorney, accountant, purchaser representative
and/or tax adviser, if any (collectively, the “Advisers”), have received the Memorandum and all other documents
requested by the Purchaser, have carefully reviewed them and understand the information contained therein.

 

(e)          Neither
the Securities and Exchange Commission nor any state securities commission or other regulatory authority has approved the Units,
the Common Stock, the Warrants, or the Warrant Shares, or passed upon or endorsed the merits of the offering of Units, or confirmed
the accuracy or determined the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other
regulatory authority.

 

(f)          All
documents, records, and books pertaining to the investment in the Units (including, without limitation, the Memorandum) have been
made available for inspection by such Purchaser and its Advisers, if any.

 

(g)          The
Purchaser and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or
persons acting on behalf of the Company concerning the offering of the Units, the business and financial condition of the Company,
and all such questions have been answered to the full satisfaction of the Purchaser and its Advisers, if any.

 

(h)          In
evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information
(oral or written) other than as stated in the Memorandum.

 

(i)          The
Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering of the Units through or as a result
of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or
other communication published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including,
without limitation, internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection
with the Offering and sale of the Units and is not subscribing for the Units and did not become aware of the Offering of the Units
through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by,
a person not previously known to the Purchaser in connection with investments in securities generally.

 

(j)           The
Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or
the like relating to this Subscription Agreement or the transactions contemplated hereby (other than commissions to be paid by
the Company to the Placement Agent or as otherwise described in the Memorandum) and, in turn, to be paid to its selected dealers.

 

(k)          The
Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters, and,
in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with
the Offering to evaluate the merits and risks of an investment in the Units and the Company and to make an informed investment
decision with respect thereto.

 

(l)          The
Purchaser is not relying on the Company, the Placement Agent or any of their respective employees or agents with respect to the
legal, tax, economic and related considerations of an investment in the Units, and the Purchaser has relied on the advice of, or
has consulted with, only our own Advisers.

 

    	 

    	 

    

 

(m)          The
Purchaser is acquiring the Units solely for such Purchaser’s own account for investment purposes only and not with a view
to or intent of resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal,
with any person to sell or transfer all or any part of the Units, the Common Stock, the Warrants, the Warrant Shares, and the Purchaser
has no plans to enter into any such agreement or arrangement.

 

(n)          The
Purchaser must bear the substantial economic risks of the investment in the Units indefinitely because none of the securities included
in the Units may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and applicable
state securities laws or an exemption from such registration is available. Legends shall be placed on the securities included in
the Units to the effect that they have not been registered under the Securities Act or applicable state securities laws. Appropriate
notations will be made in the Company’s stock books to the effect that the securities included in the Units have not been
registered under the Securities Act or applicable state securities laws. Stop transfer instructions will be placed with the transfer
agent, if any, of the securities. There can be no assurance that there will be any market for resale of the Units, the Common Stock,
the Warrants, or the Warrant Shares nor can there be any assurance that such securities will be freely transferable at any time
in the foreseeable future.

 

(o)          The
Purchaser has adequate means of providing for such Purchaser’s current financial needs and foreseeable contingencies and
has no need for liquidity of its investment in the Units for an indefinite period of time.

 

(p)          The
Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to
execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions
hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint stock
company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose
of acquiring the Units, such entity is duly organized, validly existing and in good standing under the laws of the state of its
organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of
state law or our charter or other organizational documents, such entity has full power and authority to execute and deliver this
Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and
to purchase and hold the securities constituting the Units, the execution and delivery of this Subscription Agreement has been
duly authorized by all necessary action, this Subscription Agreement has been duly executed and delivered on behalf of such entity
and is a legal, valid and binding obligation of such entity; or (iii) if executing this Subscription Agreement in a representative
or fiduciary capacity, represents that it has full power and authority to execute and deliver this Subscription Agreement in such
capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company
or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and such individual, partnership,
ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform
pursuant to this Subscription Agreement and make an investment in the Company, and represents that this Subscription Agreement
constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this Subscription Agreement will
not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the Purchaser is
a party or by which it is bound.

 

    	 

    	 

    

 

(q)         The
Purchaser and the Advisers, if any, have had the opportunity to obtain any additional information, to the extent the Company had
such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy
of the information contained in the Memorandum and all documents received or reviewed in connection with the purchase of the Units
and have had the opportunity to have representatives of the Company provide them with such additional information regarding the
terms and conditions of this particular investment and the financial condition, results of operations, business of the Company
deemed relevant by the Purchaser or the Advisers, if any, and all such requested information, to the extent the Company had such
information in its possession or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction
of the Purchaser and the Advisers, if any.

 

(r)          Any
information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Placement Agent is complete
and accurate and may be relied upon by the Company and the Placement Agent in determining the availability of an exemption from
registration under federal and state securities laws in connection with the offering of securities as described in the Memorandum.
The Purchaser further represents and warrants that it will notify and supply corrective information to the Company and the Placement
Agent immediately upon the occurrence of any change therein occurring prior to the Company’s issuance of the securities contained
in the Units.

 

(s)          The
Purchaser has significant prior investment experience, including investment in non-registered, high risk securities. The Purchaser
is knowledgeable about investment considerations in development-stage companies. The Purchaser has a sufficient net worth to sustain
a loss of its entire investment in the Company in the event such a loss should occur. The Purchaser’s overall commitment
to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial circumstances
and the purchase of the Units will not cause such commitment to become excessive. The investment is a suitable one for the Purchaser.

 

(t)          The
Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or the Advisers,
if any, consider material to the Purchaser’s decision to make this investment.

 

(u)          The
Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Memorandum were prepared
by the Company in good faith but that the attainment of any such projections, estimates or forward-looking statements cannot be
guaranteed by the Company and should not be relied upon.

 

(v)          No
oral or written representations have been made, or oral or written information furnished, to the Purchaser or the Advisers, if
any, in connection with the Offering which are in any way inconsistent with the information contained in the Memorandum.

 

(w)          Within
five (5) days after receipt of a request from the Company or the Placement Agent, the Purchaser will provide such information and
deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company or the
Placement Agent is subject.

 

(x)          The
Purchaser’s substantive relationship with the Placement Agent or subagent through which the Purchaser is subscribing for
Units predates the Placement Agent’s or such subagent’s contact with the Purchaser regarding an investment in the Units.

 

(y)          THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND
ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES
ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT
AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES
PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THE MEMORANDUM OR THIS SUBSCRIPTION AGREEMENT.
ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

 

    	 

    	 

    

 

(z)          The
Purchaser acknowledges that none of the Units, the Common Stock, the Warrants, or the Warrant Shares have been recommended by any
federal or state securities commission or regulatory authority. In making an investment decision investors must rely on their own
examination of the Company and the terms of the Offering, including the merits and risks involved. Furthermore, the foregoing authorities
have not confirmed the accuracy or determined the adequacy of this Subscription Agreement or the Memorandum. Any representation
to the contrary is a criminal offense. The Units, the Common Stock, the Warrants, and the Warrant Shares are subject to restrictions
on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, and the applicable
state securities laws, pursuant to registration or exemption therefrom. The Purchaser should be aware that it will be required
to bear the financial risks of this investment for an indefinite period of time.

 

(aa)         (For
ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed
of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan
assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification
of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision
to invest in the Company; (b) is independent of the Company or any of its affiliates; (c) is qualified to make such investment
decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation
of the Company or any of its affiliates.

 

(bb)         The
Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac> before
making the following representations. The Purchaser represents that the amounts invested by it in the Company in the Offering
were not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations,
including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among
other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities
and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at
<http://www.treas.gov/ofac>. In addition, the programs administered by OFAC (the “OFAC Programs”) prohibit
dealing with individuals1 or entities in certain countries
regardless of whether such individuals or entities appear on the OFAC lists.

 

(cc)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser;
(3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for
whom the Purchaser is acting as agent or nominee in connection with this investment is a country, territory, individual or entity
named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept
any amounts from a prospective investor if such prospective investor cannot make the representation set forth in the preceding
paragraph. The Purchaser agrees to promptly notify the Company and the Placement Agent should the Purchaser become aware of any
change in the information set forth in these representations. The Purchaser understands and acknowledges that, by law, the Company
may be obligated to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions from the
Purchaser, declining any redemption requests and/or segregating the assets in the account in compliance with governmental regulations,
and the Placement Agent may also be required to report such action and to disclose the Purchaser’s identity to OFAC. The
Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights, if any,
of the Purchaser if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable
to the Company and the Placement Agent or any of the Company’s other service providers. These individuals include specially
designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs.

 

 

1           These individuals include
specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo
programs.

 

    	 

    	 

    

 

(dd)         To
the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser;
(3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for
whom the Purchaser is acting as agent or nominee in connection with this investment is a senior foreign political figure,2
or any immediate family3 member or
close associate4 of a senior foreign political
figure, as such terms are defined in the footnotes below.

 

(ee)         If
the Purchaser is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives
deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents
and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country
in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related
to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank
to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not
have a physical presence in any country and that is not a regulated affiliate.

 

6.            Company
Representations and Warranties. The Company represents and warrants to and agrees with the Purchaser that:

 

(a)          The
Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation
and has the requisite corporate power to own its properties and to carry on its business as presently conducted. The Company is
(or will be) duly qualified as a foreign corporation to do business and is (or will be) in good standing in each jurisdiction
where the nature of the business conducted or property owned by it makes such qualification necessary.

 

 

2           A
“senior foreign political figure” is defined as a senior official in the executive, legislative, administrative, military
or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or
a senior executive of a foreign government-owned corporation. In addition, a “senior foreign political figure” includes
any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure.

 

3           “Immediate
family” of a senior foreign political figure typically includes the figure’s parents, siblings, spouse, children and
in-laws.

 

4           A
“close associate” of a senior foreign political figure is a person who is widely and publicly known to maintain an
unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial
domestic and international financial transactions on behalf of the senior foreign political figure.

 

    	 

    	 

    

 

(b)          This
Subscription Agreement and any other agreements, documents or instruments delivered or required to be delivered together with or
pursuant to this Agreement or in connection herewith (collectively “Transaction Documents”) have been duly authorized,
executed and delivered by the Company and are valid and binding agreements of the Company enforceable in accordance with their
terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors’ rights generally and to general principles of equity. The Company has full corporate
power and authority necessary to enter into and deliver the Transaction Documents and to perform its obligations thereunder.

 

(c)          The
Company has reserved and will keep available out of its authorized but unissued shares of Common Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the exercise of the Warrants.

 

7.          Registration
Rights. The Company hereby grants to the Purchaser the registration rights with respect to the shares of Common Stock and Warrant
Shares underlying the Units as described on Annex A attached hereto and incorporated herein by reference. In the event of
a conflict between such Annex A and this Subscription Agreement, the Annex A shall control.

 

8.          Indemnification.
The Purchaser agrees to indemnify and hold harmless the Company, the Placement Agent (including its selected dealers, if any),
and their respective officers, directors, employees, agents, control persons and affiliates from and against all losses, liabilities,
claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating,
preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false
acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser
of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription
Agreement.

 

9.          Irrevocability;
Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser,
except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser
and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal
representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall
be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by
and be binding upon each such person and such person’s heirs, executors, administrators, successors, legal representatives,
and permitted assigns.

 

10.         Modification.
This Subscription Agreement shall not be modified or waived except by an instrument in writing signed by the party against whom
any such modification or waiver is sought.

 

11.         Immaterial
Modifications to the Transaction Documents. The Company may, at any time prior to the First Closing, modify the Warrant in
the form of Annex B to the Memorandum and any other Transaction Document if necessary to clarify any provision therein,
without first providing notice or obtaining prior consent of the Purchaser, if, and only if, such modification is not material
in any respect.

 

12.         Notices.
Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified
mail, return receipt requested, or delivered by facsimile transmission or by e-mail transmission, or delivered against receipt
to the party to whom it is to be given (a) if to the Company, at the address set forth above, or (b) if to the Purchaser, at the
address set forth on the signature page hereof (or, in either case, to such other address as the party shall have furnished in
writing in accordance with the provisions of this Section 12). Any notice or other communication given by certified mail shall
be deemed given at the time of receipt thereof. The Purchaser agrees that notice may be served upon the Purchaser in accordance
with the foregoing procedures by the Placement Agent or other agent that introduced the Purchaser to the Company.

 

    	 

    	 

    

 

13.         Assignability.
This Subscription Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser
and the transfer or assignment of the shares of Common Stock, the Warrants or the Warrant Shares shall be made only in accordance
with all applicable laws.

 

14.         Applicable
Law. This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable
to contracts to be wholly-performed within said State, and without regard to the conflicts of laws principles thereof.

 

15.         Arbitration.
The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that:
(a) Arbitration is final and binding on the parties; (b) The parties are waiving their right to seek remedies in court, including
the right to a jury trial; (c) Pre-arbitration discovery is generally more limited and different from court proceedings; (d) The
arbitrator’s award is not required to include factual findings or legal reasoning and any party’s right to appeal or
to seek modification of rulings by arbitrators is strictly limited; and (e) The panel of arbitrators will typically include a minority
of arbitrators who were or are affiliated with the securities industry.

 

All controversies which may arise between
the parties concerning this Subscription Agreement shall be determined by arbitration pursuant to the rules then pertaining to
the American Arbitration Association in New York City, New York. The arbitration shall be governed by the Federal Arbitration Act,
9 U.S.C. Sec. 1-16, and the judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction
thereof. Any notice of such arbitration or for the confirmation of any award in any arbitration shall be sufficient if given in
accordance with the provisions of this Agreement. The parties agree that the determination of the arbitrators shall be binding
and conclusive upon them.

 

16.         Blue
Sky Qualification. The purchase of Units under this Subscription Agreement is expressly conditioned upon the exemption from
qualification of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required
to qualify this transaction under the securities laws of any jurisdiction and, should qualification be necessary, the Company shall
be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction.

 

17.         Use
of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the person or persons referred to may require.

 

18.         Confidentiality.
The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company, not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except
as may be required by law or for the performance of this Agreement, or use to the detriment of the Company or for the benefit of
any other person or persons, or misuse in any way, any confidential information of the Company, including any scientific, technical,
trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated by the Company
as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging
to the Company and confidential information obtained by or given to the Company about or belonging to third parties.

 

    	 

    	 

    

 

19.         Miscellaneous.

 

(a)          This
Subscription Agreement (including the annexes hereto), together with the Transaction Documents (which are to be issued or executed
at closing), constitute the entire agreement between the Purchaser and the Company with respect to the subject matter hereof and
supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms and
provisions of this Subscription Agreement may be waived, or consent for the departure therefrom granted, only by a written document
executed by the party entitled to the benefits of such terms or provisions.

 

(b)          The
representations and warranties and covenants of the Company and the Purchaser made in this Subscription Agreement (including the
annexes hereto) shall survive the execution and delivery hereof and delivery of the securities contained in the Units.

 

(c)          Each
of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others
engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the
transactions contemplated hereby are consummated.

 

(d)          This
Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original (including signatures
sent by facsimile transmission or by email transmission of a PDF scanned document), but all of which shall together constitute
one and the same instrument.

 

(e)          Each
provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof
are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or
affect the remaining portions of this Subscription Agreement.

 

(f)          Paragraph
titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth
in the text.

 

(g)          The
Purchaser understands and acknowledges that there may be multiple closings for this Offering.

 

[The below is intended to be blank]

 

    	 

    	 

    

Annex A to the Subscription Agreement

 

Registration Rights

 

The Company hereby grants the Purchaser
the following registration rights. It is the intention that this Annex A be made a part of and be incorporated into the
Subscription Agreement to which this Annex A is attached (the “Subscription Agreement”). Capitalized
terms used but not defined herein shall have the meanings as defined in the Subscription Agreement. All notice to be provided under
this Annex A shall be deemed duly delivered and received in accordance with Section 12 of the Subscription Agreement.

 

1.           Definitions.

 

“Effectiveness Date”
means, with respect to the Registration Statement required to be filed hereunder, the Company’s reasonable best efforts to
have such Registration Statement declared effective the 180th calendar day following the closing of the Offering; provided,
however, that in the event the Company is notified by the Securities and Exchange Commission (the “Commission”)
that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments,
the Effectiveness Date as to such Registration Statement shall be the seventh (7th) Business Day following the date
on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness
Date falls on a day that is not a Business Day, then the Effectiveness Date shall be the next succeeding Business Day.

 

“FINRA” means the Financial
Industry Regulatory Authority, Inc.

 

“Filing Date” means,
with respect to the Registration Statement required hereunder, the 90th calendar day following the closing of a certain
reverse merger transaction with a publicly-traded company, pursuant to which the Company will merge with such a publicly-traded
company through a series of transactions including a merger or other business combination transaction (the “Closing Date”).

 

“Holder” or “Holders”
means the Purchaser or the Purchaser’s permitted assigns, but solely to the extent that the subject Registrable Securities
have not been transferred, sold or assigned pursuant to the Registration Statement or in the aftermarket.

 

“Prospectus” means the
prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission
pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering
of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the
Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.

 

“Registrable Securities”
means, as of any date of determination: (a) all of the Common Stock issued in the Offering, (b) all Warrant Shares, and (c) any
securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with
respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities
(and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder
with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared
effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance
with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144
promulgated by the Commission pursuant to the Securities Act, or (c) such securities are eligible for resale without volume or
manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter
issued by counsel to the Company to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders
(assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon
which, such securities were issued or are issuable, were at no time held by any affiliate of the Company), as reasonably determined
by the Company, upon the advice of counsel to the Company.

 

    	 

    	 

    

 

“Registration Statement”
means any registration statement required to be filed hereunder pursuant to Section 2(a), including (in each case) the Prospectus,
amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all
exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration
statement.

 

“Rule 415” means Rule
415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such
Rule.

 

“Rule 424” means Rule
424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such
Rule.

 

“SEC Guidance” means
(i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission
staff and (ii) the Securities Act.

 

“Subscription Amount”
means, as to each Purchaser, the aggregate amount to be paid for Common Stock and Warrants purchased pursuant to the Subscription
Agreement, in United States dollars and in immediately available funds.

 

“Warrant Shares” means
Common Stock underlying Warrants issued in the Offering.

 

2.           Resale
Shelf Registration.

 

(a)          On
or prior to the Filing Date, the Company shall prepare and file with the Commission a Registration Statement (which shall be on
Form S-1 or if permitted in accordance with SEC Guidance and applicable rules, on Form S-3) covering the resale of all of the Registrable
Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis
pursuant to Rule 415. Subject to the terms of this Annex, the Company shall use its commercially reasonable best efforts to cause
a Registration Statement filed under this Annex (including, without limitation, under Section 3(c)) to be declared effective under
the Securities Act as promptly as possible after the filing thereof, but in any event no later than the Effectiveness Date, and
shall use its commercially reasonable best efforts to keep such Registration Statement continuously effective under the Securities
Act (or file and keep continuously effective one or more replacement Registration Statements to register all Registrable Securities)
until all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144,
or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company
to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company
pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the
“Effectiveness Period”). Notwithstanding the foregoing, the Effectiveness Period shall be no less than four
(4) years from the Closing Date, provided that less than 90% of the Warrant Shares have been exercised and sold by the holder(s)
of the Warrant(s) so exercised. The Company shall file a final Prospectus with the Commission as required by Rule 424 with respect
to each Registration Statement.

 

    	 

    	 

    

 

(b)          Notwithstanding
the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement,
the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments
to the Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to
be registered by the Commission, on such other form available to register for resale the Registrable Securities as a secondary
offering; provided, however, that prior to filing such amendment, the Company shall be obligated to use commercially
reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with
the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.

 

(c)          Notwithstanding
any other provision of this Annex, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities
permitted to be registered on a particular Registration Statement as a secondary offering, unless otherwise directed in writing
by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement
will be reduced as follows: (i) first, the Company shall reduce or eliminate any securities to be included by any Person other
than a Holder; (ii) second, the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case
that if some Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant
Shares held by such Holders); and (iii) third, the Company shall reduce Registrable Securities represented by shares of Common
Stock issued in the Offering (applied, in the case that if some of such shares of Common Stock may be registered, to the Holders
on a pro rata basis based on the total number of unregistered shares held by such Holders)

 

(d)          In
the event the Company amends the Registration Statement in accordance with the foregoing, the Holder shall be entitled to the rights
set forth in Section 6(d) of this Annex with respect to those Registrable Securities that were not registered for resale on the
Registration Statement, as amended.

 

(e)          Each
Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Annex as Exhibit A (the “Selling
Stockholder Questionnaire”) concurrently with the Holder’s subscription for the Registrable Securities.

 

3.           Registration
Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

(a)          (i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the Registrable
Securities for the Effectiveness Period, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus
supplement (subject to the terms of this Annex), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond
as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any
amendment thereto, and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) with respect to the disposition of all Registrable Securities
covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Annex) with the intended
methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so
supplemented.

 

    	 

    	 

    

 

(b)          Notify
the Placement Agent and each Holder as promptly as reasonably possible (i) when the Registration Statement has become effective,
(ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities
or the initiation of any governmental action, litigation, hearing or other proceeding (“Proceedings”) for that
purpose, and (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose.

 

(c)          Use
its commercially reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping
or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification)
of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(d)          Subject
to the terms of this Annex and applicable law, consent to the use of such Prospectus and each amendment or supplement thereto by
each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and
any amendment or supplement thereto.

 

(e)          Prior
to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification)
of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within
the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom)
effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition
in such jurisdictions of the Registrable Securities covered by the Registration Statement; provided, that, the Company shall not
be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any
material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such
jurisdiction.

 

(f)          If
requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing
Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free,
to the extent permitted by the Subscription Agreement, of all restrictive legends, and to enable such Registrable Securities to
be in such denominations and registered in such names as any such Holder may request.

 

(g)        Comply
with all applicable rules and regulations of the Commission.

 

(h)          Furnish
to each Holder such number of copies of the Prospectus included in the Registration Statement (including any preliminary Prospectus)
and any supplement thereto (in each case including all exhibits and documents incorporated by reference therein) and such other
documents as such Holder may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such
Holder.

 

(i)          Use
best efforts to file with the Commission in a timely manner all reports and other documents required of the Company under the Securities
Act and the Exchange Act.

 

    	 

    	 

    

 

(j)          Furnish
to any Holder so long as the Holder owns Registrable Securities, promptly upon request, a written statement by the Company as to
its compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act.

 

4.           
Registration Expenses. All fees and expenses incident to the performance of or compliance with this Annex by the Company shall
be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. In no event however
shall the Company be responsible for any broker or similar commissions of any Holder or any legal fees or other costs of the Holders.

 

5.           Indemnification.

 

(a)          Indemnification
by the Company. The Company shall, notwithstanding any termination of this Annex, indemnify and hold harmless each Holder,
the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal
as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and
any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and
any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or
any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all
losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively,
“Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material
fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto,
preliminary prospectus, free writing prospectus (as defined in Rule 405 promulgated under the Securities Act),or arising out of
or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading
or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or
any rule or regulation thereunder, in connection with the performance of its obligations under this Annex, except to the extent,
but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished
in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder
or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing
by such Holder expressly for use in a Registration Statement, such Prospectus, preliminary prospectus, free writing prospectus,
or in any amendment or supplement thereto (it being understood that the Holder has approved the contents of the Selling Stockholder
Questionnaire for this purpose) or (ii) the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after
the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by
such Holder. The Company shall notify the Holders promptly of the institution, threat or assertion of any governmental action,
litigation, hearing or other proceeding arising from or in connection with the transactions contemplated by this Annex of which
the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders.

 

    	 

    	 

    

 

(b)          Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers,
agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted
by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: (x) such Holder’s
failure to comply with any applicable prospectus delivery requirements of the Securities Act through no fault of the Company or
(y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, preliminary
prospectus, free writing prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission or
alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any
Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but
only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder
to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the
extent, that such information relates to such Holder’s proposed method of distribution of Registrable Securities and was
reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it being understood that
the Holder has approved the contents of the Selling Stockholder Questionnaire for this purpose), such Prospectus, preliminary prospectus,
free writing prospectus, or in any amendment or supplement thereto or (iii) to the extent, but only to the extent, related to the
use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in
writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder. In no event shall the liability
of any selling Holder under this Section 5(b) be greater in amount than the dollar amount of the net proceeds received by such
Holder upon the sale of the Registrable Securities giving rise to such indemnification obligation.

 

(c)          Conduct
of Indemnification Proceedings. (i) If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the
defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees
and expenses incurred in connection with defense thereof; provided, that, the failure of any Indemnified Party to give such notice
shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Annex, except (and only) to the extent
that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further
review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.

 

(ii)      An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3)
the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if
the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party
notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party,
the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than
one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement
of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying
Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect
of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from
all liability on claims that are the subject matter of such Proceeding.

 

    	 

    	 

    

 

(iii)        Subject
to the terms of this Annex, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this
Section) shall be paid to the Indemnified Party, as incurred, within ten Business Days of written notice thereof to the Indemnifying
Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and
expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction
(which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.

 

(d)          Contribution.   (i)
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified
Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified
Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection
with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.
The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether
any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of
a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party,
and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement
or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations
set forth in this Annex, any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any
Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in
this Section was available to such party in accordance with its terms.

 

(ii)         The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in
the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute
pursuant to this Section 5(d), in the aggregate, any amount in excess of the amount by which the net proceeds actually received
by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such
Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

(iii)        The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties.

 

6.         Miscellaneous.

 

(a)          Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Annex, each Holder or
the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Annex, including
recovery of damages, shall be entitled to specific performance of its rights under this Annex. Each of the Company and each Holder
agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any
of the provisions of this Annex and hereby further agrees that, in the event of any action for specific performance in respect
of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.

 

(b)          Compliance.
Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable
to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration
Statement.

 

    	 

    	 

    

 

(c)          Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company
of the occurrence of any event that makes the Registration Statement outdated, defective or otherwise unavailable, such Holder
will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing
by the Company or an agent of the Company that the use of the applicable Prospectus (as it may have been supplemented or amended)
may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly
as is practicable, and shall advise each Holder thereof as promptly as practicable in writing.

 

(d)          Piggy-Back
Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all
of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement
relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities,
other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity
securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection
with the Company’s stock option or other employee benefit plans, then the Company shall deliver to each Holder a written
notice of such determination and, if within fifteen business days after the date of the delivery of such notice, any such Holder
shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities
such Holder requests to be registered; provided, however, that the Company shall not be required to register any Registrable Securities
pursuant to this Section 6(d) that are the subject of a then effective Registration Statement. The registration of the Registrable
Securities pursuant to this Section 6(d) shall not be considered the satisfaction of the requirements of the Company pursuant to
Sections 2 and 3 of this Annex, subject to Section 2(d).

 

    	 

    	 

    

 

To subscribe for Units in the private offering of Pubco:

 

		1.	Date and Fill in the number of Units being purchased and Complete and Sign the Signature Page of the Subscription
Agreement.

 

		2.	Initial the Accredited Investor Certification page attached to this letter.

 

		3.	Complete and return the Investor Profile and, if applicable, Wire Transfer Authorization attached to this letter.

 

		4.	If you are a client of Merriman Capital, Inc. fax all forms to Marta Zylka of Merriman Capital, Inc. at 646-349-1170
and then send all signed original documents with check to:

 

Merriman Capital, Inc.

Attention: Marta Zylka

711 5th Avenue, 16th Floor

New York, New York 10022

 

		5.	If you are not a client of Merriman Capital, Inc.
fax all forms to your registered representative.

 

		6.	Please make your subscription payment payable to the order of “Signature Bank, Escrow Agent for Bionik Laboratories
Inc.” 

 

For wiring funds directly to the escrow account,
see the following instructions:

 

Acct Name: Signature Bank as Escrow Agent for
Bionik Laboratories Inc.

Acct #: 1502342777

 

Signature Bank 

ABA/Routing #: 026013576

SWIFT Code: SIGNUS33

950 Third Ave, 9th FL

New York, NY 10022

Attn: PCG# 311

 

FBO: Investor Name 

Social Security Number

Address

 

Thank you for your interest,

 

Merriman Capital, Inc. and its’ Sub-Agents

 

    	 

    	 

    

 

ANTI MONEY LAUNDERING REQUIREMENTS 

 

	
        The USA PATRIOT Act

         
	What is money laundering?	How big is the problem and why is it important?
	
         

        The USA PATRIOT Act is designed to detect, deter, and punish
        terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage firms and financial
        institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money laundering programs.

         

        To help you understand these efforts, we want to provide you
        with some information about money laundering and our steps to implement the USA PATRIOT Act.
	
         

        Money laundering is the process of disguising
        illegally obtained money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection
        with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.
	
         

        The use of the U.S. financial system by
        criminals to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department,
        one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

 

	What are we required to do to eliminate money laundering?
	
         

        Under rules required by the USA PATRIOT Act, our anti-money
        laundering program must designate a special compliance officer, set up employee training, conduct independent audits, and establish
        policies and procedures to detect and report suspicious transaction and ensure compliance with such laws.
	
         

        As part of our required program, we may ask you to provide various
        identification documents or other information. Until you provide the information or documents we need, we may not be able to effect
        any transactions for you.

 

    	 

    	 

    

 

BIONIK LABORATORIES INC.

SIGNATURE PAGE TO THE

SUBSCRIPTION AGREEMENT

 

Subscriber hereby elects to subscribe under the Subscription
Agreement for a total of ______ Units at a price of $0.80 per Unit (NOTE: to be completed by subscriber) and executes the Subscription
Agreement.

 

Date (NOTE: To be completed by subscriber): __________________

 

If the Purchaser is an
INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, as COMMUNITY PROPERTY, or as an INDIVIDUAL RETIREMENT ACCOUNT:

  

	 	 	 	 	 
	 	Print Name(s)	 	Social Security Number(s)	 
	 	 	 	 	 
	 	 	 	 	 
	 	Signature(s) of Subscriber(s)	 	Signature	 
	 	 	 	 	 
	 	 	 	 	 
	 	Date	 	Address	 

 

If the Purchaser is a
PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:

 

	 	 	 	 	 
	 	
        Name of Partnership,

        Corporation, Limited

        Liability Company
        or Trust
	 	
        Federal Taxpayer

        Identification Number
	 
	 	 	 	 	 
	 	By:	 	 	 	 
	 	 	Name:	 	State of Organization	 
	 	 	Title:	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	Date	 	Address	 

 

	BIONIK LABORATORIES INC.	 
	 	 	 
	By:	 	 
	 	Authorized Officer	 

 

    	 

    	 

    

BIONIK LABORATORIES INC.

 

ACCREDITED INVESTOR CERTIFICATION

 

For Individual Investors Only

(all Individual Investors must INITIAL
where appropriate):

 

	Initial	 	 	I have a net worth in excess of $1 million, either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse. For purposes of the foregoing net worth calculation, I have excluded the value of my/our primary residence, after deducting any mortgage securing such primary residence). 
	 	 	 
	Initial	 	 	I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 	 
	Initial	 	 	I am a director or executive officer of Bionik Laboratories Inc.
	 	 	 

For Non-Individual Investors

(all Non-Individual Investors must INITIAL
where appropriate):

 

	Initial	 	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above. 
	 	 	 
	Initial	 	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least $5 million and was not formed for the purpose of investing in the Company.
	 	 	 
	Initial	 	 	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment adviser.
	 	 	 
	Initial	 	 	The investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Agreement.
	 	 	 
	Initial	 	 	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet either of the criteria for Individual Investors.
	 	 	 
	Initial	 	 	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 	 
	Initial	 	 	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial	 	 	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 	 
	Initial	 	 	The investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial	 	 	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of $5,000,000.
	 	 	 
	Initial	 	 	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act, or a registered investment company.
	 	 	 

 

    	 

    	 

    

 

Bionik Laboratories Inc.

Investor Profile

(Must be completed by Investor)

 

Section A - Personal Investor Information

 

	Investor Name(s): _____________________________________________________________________________________
	 
	Individual executing Profile or Trustee:
    _____________________________________________________________________________________________________
	 
	Social Security Numbers / Federal I.D. Number:
____________________________________________________________________________________________________

 

	Date of Birth:____________________  	 	Marital Status:__________________________________
	 	 	 
	Joint Party Date of Birth:____________________   	 	Investment Experience (Years): _____________________
	 	 	 
	Annual Income:____________________   	 	Liquid Net Worth: _______________________________

 

Net Worth (excluding value of primary residence, after deducting
any mortgage securing such residence): ____________________________________________________________________________________________________

 

	Tax Bracket:	______ 15% or below	_____ 25% - 27.5%	_____ Over 27.5%

 

Investment Objectives (check one or more):

 

____ Preservation of Capital

____ Income

____ Capital Appreciation

____ Trading Profits

____ Speculation

____ Other (please specify)

* See definitions on following pages

 

	Home Street Address: _____________________________________________________________________________________________________

 

	Home City, State & Zip Code: ____________________________________________________________________________________________________

 

	Home Phone: _________________	Home Fax: _________________	Home Email: ________________

 

	Employer: __________________________________________________________________________________________
	 
	Employer Street Address: ____________________________________________________________________________________________________

 

    	 

    	 

    

 

 

	Employer City, State & Zip Code: ___________________________________________________________________________________________________

 

	Bus. Phone: _________________	Bus. Fax: __________________	Bus. Email: ___________________

 

	Type of Business: ________________________________________________________________________________________________
	 
	________________________________________________________________________________________________

 

If you are a United States citizen, please list
the number and jurisdiction of issuance of any other government-issued document evidencing residence and bearing a photograph
or similar safeguard (such as a driver’s license or passport), and provide a photocopy of each of the documents
you have listed or indicate that such documentation has already been previously provided pursuant to your brokerage account. _______________________________________________________________________________________________

 

If you are NOT a United States citizen,
for each jurisdiction of which you are a citizen or in which you work or reside, please list (i) your passport number and country
of issuance or (ii) alien identification card number AND (iii) number and country of issuance of any other government-issued
document evidencing nationality or residence and bearing a photograph or similar safeguard, and provide a photocopy of each of
these documents you have listed or indicate that such documentation has already been previously provided pursuant to your brokerage
account.. These photocopies must be certified by a lawyer as to authenticity.

_________________________________________________________________________________________

 

Section B – Certificate Delivery
Instructions

 

All certificates will be delivered for deposit in your
brokerage account with your corresponding registered representative. If you do not wish for the certificates to be delivered to
your brokerage account, please indicate below:

 

____ Please deliver certificate to the Employer Address listed
in Section A.

____ Please deliver certificate to the Home Address listed in
Section A.

____Please deliver certificate to the following address:

_____________________________________________________________________________________________

 

Section C – Form of Payment
– Check or Wire Transfer

 

____ Check payable to Signature Bank, as Escrow Agent for
Bionik Laboratories Inc.

____ Wire funds from my outside account
according to the “How to subscribe for Units” Page.

____ Wire funds from my Merriman Capital, Inc. Account or my
account with my registered representative who is not part of Merriman Capital, Inc. - See the “Wire Transfer Authorization”
Page.

____
The funds for this investment are rolled over, tax deferred from __________ within the allowed 60 day window.

Please check if you are a FINRA member or affiliate of a FINRA
member firm: ________

 

	 	 	 
	Investor Signature	 	Date

 

    	 

    	 

    

 

Certain Definitions

 

Investment Objectives: The typical investment listed
with each objective are only some examples of the kinds of investments that have historically been consistent with the listed objectives.
However, neither Bionik Laboratories Inc. nor Merriman Capital, Inc. can assure that any investment will achieve your intended
objective. You must make your own investment decisions and determine for yourself if the investments you select are appropriate
and consistent with your investment objectives.

 

Neither Bionik Laboratories Inc. nor Merriman Capital, Inc.
assumes responsibility to you for determining if the investments you selected are suitable for you.

 

Preservation of Capital: An investment objective of Preservation
of Capital indicates you seek to maintain the principal value of your investments and are interested in investments that have
historically demonstrated a very low degree of risk of loss of principal value. Some examples of typical investments might include
money market funds and high quality, short-term fixed income products.

 

Income: An investment objective of Income indicates
you seek to generate Income from investments and are interested in investments that have historically demonstrated a low
degree of risk of loss of principal value. Some examples of typical investments might include high quality, short and medium-term
fixed income products, short-term bond funds and covered call options.

 

Capital Appreciation: An investment objective of Capital
Appreciation indicates you seek to grow the principal value of your investments over time and are willing to invest in securities
that have historically demonstrated a moderate to above average degree of risk of loss of principal value to pursue this objective.
Some examples of typical investments might include common stocks, lower quality, medium-term fixed income products Equity mutual
funds and index funds.

 

Trading Profits: An investment objective of Trading
Profits indicates you seek to take advantage of short-term trading opportunities, which may involve establishing and liquidating
positions quickly. Some examples of typical investments might include short-term purchases and sales or volatile or low priced
common stocks, put or call options, spreads, straddles and/or combinations on equities or indexes. This is a high-risk strategy.

 

Speculation: An investment objective of Speculation
indicates you seek a significant increase in the principal value of your investments and are willing to accept a corresponding
greater degree of risk by investing in securities that have historically demonstrated a high degree of risk of loss of principal
value to pursue this objective. Some examples of typical investments might include lower quality, long-term fixed income products,
initial public offerings, volatile or low priced common stock, the purchase of sale of put or call options, spreads, straddles
and/or combinations on equities or indexes, and the use of short-term or day trading strategies.

 

Other: Please specify.

 

    	 

    	 

    

 

Memorandum

Wire Transfer Authorization

 

TO:

 

	RE:	Client Wire Transfer Authorization
	 	Bionik Laboratories Inc.

 

DATE: ________________

 

 

 

This memorandum authorizes the
transfer of the following listed funds from my Brokerage Account as follows:

 

	Brokerage Account #	 	 

 

	Wire Amount	$_______________________________________________	 

 

	BANK NAME:  	 	 	 
	ABA NUMBER: 	 	 	 
	A/C NAME: 	[          ], AS AGENT FOR 	 	 
	A/C Number:  		 	 

 

	 	REFERENCE: 	 
	 	SUBSCRIBER LEGAL NAME 	 
	 	 	 
	 	 	 
	 	TAX ID NUMBER	 
	 	 	 
	 	 	 
	 	SUBSCRIBER ADDRESS	 
	 	 	 

 

	FBO:	 	 
	 	 	 
	Investment Title:	 	 
	 	 	 
	Signature:	 	 
	 	 	 
	Signature:	 	 
	 	(Joint Signature)	 

 

    	 

    	 

    

 

Annex B To The Subscription Agreement

 

BIONIK LABORATORIES INC.

 

Plan Of Distribution

 

Each selling stockholder
of the securities offered hereby and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility
on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder
may use any one or more of the following methods when selling securities:

 

		·	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		·	block trades in which the broker-dealer will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction;

 

		·	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		·	an exchange distribution in accordance with the rules of the applicable exchange;

 

		·	privately negotiated transactions;

 

		·	settlement of short sales entered into after the effective date of the registration statement of
which this prospectus is a part;

 

		·	in transactions through broker-dealers that agree with the selling stockholders to sell a specified
number of such securities at a stipulated price per security;

 

		·	through the writing or settlement of options or other hedging transactions, whether through an
options exchange or otherwise;

 

		·	a combination of any such methods of sale; or

 

		·	any other method permitted pursuant to applicable law.

 

The selling stockholders
may also sell securities under Rule 144 under the Securities Act of 1933, as amended (or the Securities Act), if available, rather
than under this prospectus.

 

Broker-dealers engaged
by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction
a markup or markdown in compliance with FINRA IM-2440.

 

    	 

    	 

    

 

In connection with
the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions
they assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions,
or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which
securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended
to reflect such transaction).

 

The selling stockholders
and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within
the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities. In no event shall any broker-dealer receive
fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).

 

We are required to
pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the selling
stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

Because selling stockholders
may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the prospectus
delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus
which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus.
The selling stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed
sale of the resale securities by the Selling Stockholders.

 

We have agreed to keep
this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling stockholders without
registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
us to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other
rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under
applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they
have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with.

 

Under applicable rules
and regulations under the Securities Exchange Act of 1934, as amended (or the Exchange Act), any person engaged in the distribution
of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable
restricted period, as defined in Regulation M promulgated under the Exchange Act, prior to the commencement of the distribution.
In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations
thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the
selling stockholders or any other person. We will make copies of this prospectus available to the selling stockholders and have
informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).

 

    	 

    	 

    

 

Annex C to the Subscription
Agreement

 

BIONIK LABORATORIES INC.

 

Selling Stockholder Notice and Questionnaire

 

The undersigned beneficial
owner of common stock and warrants (the “Registrable Securities”) of Bionik Laboratories Inc., a [_____] corporation
(the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange
Commission (the “Commission”) a registration statement (the “Registration Statement”) for
the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”),
of the Registrable Securities, in accordance with the terms of the Subscription Agreement (the “Subscription Agreement”)
to which this document is annexed. A copy of the Subscription Agreement is available from the Company upon request at the address
set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Subscription
Agreement.

 

Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders
and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned beneficial
owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it in the Registration Statement.

 

The undersigned hereby
provides the following information to the Company and represents and warrants that such information is accurate:

QUESTIONNAIRE

 

	1.	Name.

 

	 	(a)	Full Legal Name of Selling Stockholder

	
         

         

 

	 	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:

 

	
        

         

 

	 	(c)	Full Legal Name of Natural Control Person(s) (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):

 

    	 

    	 

    

 

2. Address for Notices to Selling
Stockholder.

 

	
          

	 
	 
	

Telephone: _______________________________________________________________________________
	 
	Fax: _______________________________________________________________________________
	 
	Contact Person: _______________________________________________________________________________

 

3. Broker-Dealer Status.

 

	 	(a)	Are you a broker-dealer?
	 	 	 
	Yes    ̈ No    ̈ 
	 
	 	(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
	 	 	 
	Yes    ̈ No    ̈ 
	 
	 	Note: 	If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.
	 	 	 
	 	(c)	Are you an affiliate of a broker-dealer?
	 	 	 
	Yes    ̈ No    ̈ 
	 
	 	(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
	 	 	 
	Yes    ̈ No    ̈ 

 

	 	Note:	If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

4. Beneficial Ownership of Securities
of the Company Owned by the Selling Stockholder.

 

Except as set forth below
in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities
issuable pursuant to the Subscription Agreement.

 

    	 

    	 

    

 

	 	(a)	     Type and Amount of other securities beneficially owned by the Selling Stockholder:

 

	 	 

 

5. Relationships with the Company.

 

Except as set forth below,
neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the
equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company
(or its predecessors or affiliates) during the past three years.

 

			State any exceptions here:

	 	 
		 
	 	 

		 

 

6. Plan of Distribution.

 

The undersigned
confirms whether the Plan of Distribution attached as Annex B to the Subscription Agreement is acceptable.

 

Yes  ̈
       No  ̈

 

The undersigned agrees
to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective. By signing below, the undersigned consents to the disclosure
of the information contained herein in its answers to Items 1 through 6 and the inclusion of such information in the Registration
Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information
will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related
prospectus and any amendments or supplements thereto.

 

IN WITNESS WHEREOF
the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
or by its duly authorized agent.

 

	Date: 	__________________________	 
	 	 	 
	Name of Beneficial Owner (print): 	__________________________	 
	 	 	 
	Signature (individual): 	__________________________	 
	 	 	 
	Signature (corporate):	__________________________	 

 

	By: 	 	 	 

	 	Name:	 	 
	 	Title:	 	 

 

    	 

    	 

    

 

PLEASE FAX A COPY
(OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, 

 

Ruskin Moscou Faltischek, P.C.

Attention: Stephen E. Fox, Esq.

East Tower, 15th Floor

1425 RXR Plaza

Uniondale, NY 11556

sfox@rmfpc.com

Fax: (516) 663-6780Exhibit 10.9

 

EMPLOYMENT AGREEMENT

 

THIS AGREEMENT
is signed on 7th July 2014.

B E T W E E N:

BIONIK LABORATORIES INC., a corporation
incorporated under the laws of Canada (hereinafter referred to as the "Company"),

 

- and -

 

Peter Bloch, an individual resident
in the City of Toronto in the Province of Ontario (hereinafter referred to as the "Employee"),

 

WHEREAS the Company is engaged in
the business of the Medical Device Research, Development and production;

 

AND WHEREAS the Company and the
Employee have agreed to enter into an employment relationship upon the terms and subject to the conditions hereinafter set forth;

 

THIS AGREEMENT witnesses that the
parties have agreed that the terms and conditions of the relationship shall be as follows:

 

ARTICLE 1 - EMPLOYMENT AND DUTIES

 

1.1 Appointment. Subject to the
terms and conditions of this Agreement, the Company hereby agrees to employ the Employee, and the Employee hereby accepts employment
in the Position of Chief Executive Officer (the "Position"), since March 9th ,2013, and previously CFO since
January 2012,(the "Start Date").

 

1.2 Reporting and Duties. The Employee
shall report to The Board of Directors. The Employee shall perform the duties and responsibilities of Chief Executive Officer in
the area of Strategic Direction and Business Planning, including the following;

 

(i)          Overall
management of the company, including regulatory, clinical and business strategy.

 

(ii)         All
financial functions and reporting — including tax, budgeting and expense control

 

(iii)        Accessing
grant funding

 

    	 

    	 

    

 

(iii)        Relationship
management — board of directors, rehab hospitals, clinical investigators, medical director and Medical Advisory Board, regulatory
and clinical consultants, company spokespersons, including oversight of Hospital and institutional relationships.

 

(iv) Human Resources .

 

(v)         Management
of the corporate legal governance, documentation and agreements.

 

(vi)        Shareholder
relations

 

(vii)       Future
— further develop board and advisory board.

 

The Employee
agrees to comply with all applicable policies and rules of Company.

 

1.3 Term. The Employee shall be
employed on an indefinite basis, subject to the termination provisions set out in this Agreement and to any amendments as may from
time to time be agreed to in writing by the Employee and the Company.

 

1.4 Duties and Responsibilities.
The Employee shall during his period of his employment devote a normal full time employment, and devote his attention and ability
to the business and affairs of the Company, including his role in his Position and other duties, if any, and shall faithfully and
honestly serve the Company throughout his employment and use his best efforts to promote the interests of the Company. In addition,
the Employee shall truly and faithfully account for and deliver to the Company or, where applicable, any subsidiary or other affiliate
of the Company (collectively, the Subsidiaries"), all money, securities and things of value belonging to the Company or the
Subsidiaries which the Employee may from time to time receive for, from or on account of the Company or the Subsidiaries.

 

ARTICLE 2 – COMPENSATION

 

2.1           Base
Salary. The Employee will receive fixed remuneration for his employment pursuant to this Agreement consisting of an annual
monthly base salary of Canadian Twenty CDN$20,000.00, pay in arrears, and subject to applicable statutory deductions required by
law. This salary will increase to US$22,916.67 a month on the completion of a successful Reverse Takeover (RTO) transaction. The
Employee's salary will be reviewed on an annual basis to determine potential increases based on the Employee's performance and
that of the Company.

 

2.2           Options.
The Employee will be granted xxx options on the date of completion of the RTO transaction, at the price of the RTO financing transaction.
The options will vest 1/3 per year over the following 3 years and be subject to the additional terms of the Company's stock option
plan.

 

    	 

    	 

    

 

 2.3           Bonus.
The Employee shall be entitled to a target annual bonus of 50% of base salary, payable based on performance in the previous fiscal
year ending March 31. The bonus will be determined based on the achievement of the employee's objectives that will be agreed to
with the Board of Directors subsequent to the completion of the RTO.

 

2.4           Benefits.
The Employee shall be entitled to participate in all of the Company's benefit plans generally available to its employees and executives
from time to time in accordance with the terms thereof and the participation and full coverage of the Employee in such plans shall
become fully effective as of the commencement of his employment under this Agreement. The Company reserves the right to alter,
amend, replace or discontinue the benefit plans it makes available to its employees at any time, with or without notice. In addition
the Employee will be entitled to participate in the Company's Stock Option Plan as designated by the CEO of the Company based on
the terms of the Stock Option Plan. The granting of any options is conditional on the written approval of the Board of Directors
and the Company reserves the right to alter, amend, replace or discontinue this plan at any time, with or without notice to the
Employee.

 

2.5           Vacation.
The Employee shall be entitled to four (4) weeks' vacation per calendar year. Such vacation shall be taken at a time or times acceptable
to the Company having regard to its operations. The Employee shall be allowed to carry forward any unused vacation into the next
calendar year with the prior written approval of the Board of Directors.

 

2.6           Expense
Reimbursement. The Employee shall be reimbursed for all reasonable expenses actually and properly incurred by him in connection
with the performance of his duties hereunder. The Employee shall submit to the Company written, itemized expense accounts, together
with supporting invoices, acceptable to the Company and such other additional substantiation and justification as the Company
may reasonably request within sixty (60) days after the expenses have been incurred.

 

ARTICLE 3 – COVENANTS

 

3.1           Confidential
Information. The Employee hereby acknowledges that, by reason of his employment with the Company, he has and will acquire information
about certain matters and things which are confidential to the Company and the Subsidiaries (the "Confidential Information"),
and which Confidential Information is the exclusive property of the Company and/or the Subsidiaries, respectively. The Confidential
Information includes, without limitation, information concerning the Company's and the Subsidiaries' strategic plans, product research
and development plans, details and results, trade secrets, supplier lists, data, work product developed by or for the Company or
the Subsidiaries, and all other data and information concerning the business and affairs of the Company and the Subsidiaries. Notwithstanding
anything to the contrary contained herein, for the purposes hereof, Confidential Information shall not include:

 

    	 

    	 

    

 

(a)          any
information that has entered or enters the public domain through lawful means; or

 

(b)          information
which the Employee is required to disclose pursuant to applicable law, policies or due processes of applicable regulatory bodies
or legal or regulatory proceedings; provided that the Employee provides the Company with prompt notice of same and assists the
Company in seeking to prevent or limit such requirement.

 

He shall not (except in the performance
of his responsibilities) directly or indirectly, (i) use for his own benefit or for the benefit of others; (ii) disseminate, publish
or disclose; or (iii) authorize or permit the use, dissemination or disclosure by any person, firm or entity of any Confidential
Information without the express written consent of the board of directors of the Company and the Subsidiaries. Upon termination
of this Agreement for any reason, the Employee agrees to return to the Company and its Subsidiaries (or, in the case of electronic
items, permanently delete) all documents, records, storage, data, samples, and other property of the Company and its Subsidiaries,
together with all copies thereof which contain or incorporate any Confidential Information.

 

3.2           Intellectual
Property, Inventions and Patents.

 

The Employee shall take all precautions
to maintain and protect the legal rights of the Company and its Subsidiaries in the Work Product, and to maintain the confidentiality
of trade secrets included in the Work Product in accordance with Section 3.1 hereof. For certainty, no license to the Work Product
is granted to the Employee, except to the extent required for the performance of his responsibilities under this Agreement.

 

The Employee hereby covenants that the
Work Product will not violate or infringe any intellectual property rights of any third party or constitute an unauthorized use
of confidential or proprietary information of a third party.

 

All of the aforesaid covenants in this
Section shall he binding on the assigns, executors, administrators and other legal representatives of the Employee.

 

3.3           Non-Solicitation
of Employees. The Employee shall not, during the period from the date hereof to that date which is one (1) year following the
termination of this Agreement or the Employee's employment, for any reason, directly or indirectly,
hire any employees or consultants of the Company or the Subsidiaries or induce or attempt to induce, solicit or attempt to solicit
any of the employees or consultants of the Company or the Subsidiaries to leave their employment or engagement with the Company.

 

    	 

    	 

    

 

3.4           Non-Solicitation
of Customers and Suppliers. The Employee shall not, during the period from the date hereof to that date which is one (1) year
following the termination of this Agreement or the termination of the Employee's employment, for any reason, directly or indirectly,
without the prior written consent of the Company, solicit or attempt to solicit any customers of the Company or the Subsidiaries
with whom the Employee had contact with or material knowledge of, for the purpose of selling to those customers any products or
services which are the same as or substantially similar to or in any way competitive with the products or services sold by the
Company or the Subsidiaries, at the time of termination of this Agreement. The Employee shall not, during the period from the date
hereof to that date which is one (1) year following the termination of this Agreement or the termination of the Employee's employment,
for any reason, directly or indirectly, without the prior written consent of the Company, solicit or attempt to solicit any suppliers
of the Company or the Subsidiaries with whom the Employee had contact with or material knowledge of, for the purpose of diverting
or attempting to divert business away from the Company or the Subsidiaries.

 

3.5           Non-Competition.
Subject as hereinafter provided, the Employee shall not, without the prior written consent of the Board of Directors of the Company
at any time during the period from the date hereof to that date which is one (1) year following the date of termination this Agreement
or the Employee's employment, engage in the development of similar medical devices or devices that are in any way competitive with
the products or services sold by the Company or the Subsidiaries at the time of the termination of this Agreement, either individually
or in partnership or jointly or in conjunction with any person as principal, agent, employee, shareholder (other than a holding
of shares listed on a Canadian or United States stock exchange that does not exceed five percent (5%) of the outstanding shares
so listed) or in any other manner whatsoever, nor shall the Employee lend money to, guarantee the debts or obligations of or permit
his name or any part thereof to be used or employed by any person engaged in a similar business to the Company or the Subsidiaries.

 

3.6           Acknowledgement,
Waiver and Enforcement. The Employee confirms that the restrictions contained in this Article 3 are reasonable and valid to
protect the legitimate business interests of the Company and the Subsidiaries. The Employee hereby agrees and acknowledges that
it would be extremely difficult to measure the damages that might result from any breach of any of the covenants of the
Employee contained herein and that any breach of any of the covenants of the Employee might result in irreparable injury to the
business for which monetary damages could not adequately compensate. If a breach of any of the covenants of the Employee occurs,
the Company shall be entitled, in addition to any other rights or remedies the Company may have at law or in equity, to have an
injunction issued by any competent court enjoining and restricting the Employee and all other parties involved therein from continuing
such breach.

 

3.7           Survival
and Enforceability. It is expressly agreed by the parties hereto that the provisions of this Article 3 shall survive the termination
of this Agreement and the Employee's employment.

 

    	 

    	 

    

 

ARTICLE 4 – DEATH

 

4.1           Death.
If the Employee dies while employed under this Agreement, this Agreement shall terminate immediately and the Company shall pay
to the Employee's estate, the annual salary and a portion of the annual bonus earned by the Employee up to the date of his death.
All options and warrants vested in the Employee prior to the date of his death shall continue in full force and effect, subject
to the terms and conditions of the Stock Option Plan.

 

ARTICLE 5 - TERMINATION OF EMPLOYMENT

 

5.1           Termination
by Company for Cause. The Company may terminate this Agreement for cause at any time without any notice or payment in lieu
of such notice of termination. The Employee will be provided with his annual salary, benefits as set out in Section 2.2, and expenses
incurred up to the date of termination. For the purposes of this Agreement, "cause" includes:

 

(a)          a
material breach by the Employee of the terms of this Agreement; and

 

(b)          any
act or conduct that would constitute cause at common law.

 

5.2           Termination
by Disability. The Company may terminate this Agreement as a result of any mental or physical disability or illness which results
in the Employee being unable to substantially perform his duties for a continuous period of 150 days or for periods aggregating
180 days within any period of 365 days. Permanent or indefinite inability to perform essential functions shall be based on the
opinion of a qualified medical provider if a medical condition is involved, or as otherwise required by law. Termination will be
effective on the date designated by Company and the Employee will be paid his annual salary, benefits and a portion of the annual
bonus as set out in Section 2.2, and expenses incurred up to the date of termination.

 

5.3           Termination
by Employee. The Employee may terminate this Agreement and his employment at any time, for any reason, provided that the Employee
provides the Company with thirty (30) days' prior written notice. The Employee agrees to use his best effort to assist the Company
to complete an effective reallocation of his responsibilities upon the giving of such notice. The Company may waive notice, in
whole or in part, by providing the Executive pay in lieu of notice for the balance of the thirty (30) day period, including benefits
as set out in Section 2.2 and expenses incurred.

 

    	 

    	 

    

 

5.4           Termination
by Company for Other than Cause. The Company may terminate this Agreement and the Employee's employment, for any reason without
cause, provided that the Company provides the Employee pay in lieu of notice, equal to 12 months plus one month for each completed
year of service of salary, bonus and full benefits. In the event of termination by the Company for reasons other than cause, the
Employee's benefits in Section 2.2 will be maintained. The Employee will have 6 months after termination to exercise all vested
options in accordance with the terms of the Stock Option Plan. All unvested option immediately forfeit upon the Employee being
provided with notice of termination of his employment.

 

5.5           Limitation
of Liability. The Employee acknowledges, understands and agrees that the notice/pay in lieu of notice arid other benefits provided
for above represent the Company's maximum termination and severance obligations to the Employee. No other notice or severance entitlements
shall apply. This provision shall remain in full force and effect unamended, notwithstanding any other alterations to the terms
and conditions of the Employee's employment, unless agreed to by the Company in writing. The Employee also acknowledges, understands
and agrees that the giving of notice or the payment of pay in lieu of notice by the Company to the Employee on termination of the
Employee's employment shall not prevent the Company from alleging cause for the termination.

 

5.6           Effect
of Termination. Upon any termination of this Agreement, the Employee shall immediately deliver or cause to be delivered to
the Company all Confidential Information and company property belonging to the Company which are in the possession, charge, control
or custody of the Employee.

 

ARTICLE 6 - GENERAL

 

6.0           Release.
Upon any termination of this Agreement or the Employee's employment, the Employee agrees to release the Company, the Subsidiaries,
and all officers, directors and employees of the Company or Subsidiaries from all actions, causes of action, claims or demands
as a result of such termination, except as otherwise expressly provided in this Agreement. Upon compliance with the applicable
termination provisions of this Agreement by the Company, the Employee agrees to deliver to the Company a full and final
written release of and from all actions or claims in connection with this Agreement and the Employee's employment in favour of
the Company, the Subsidiaries, and their directors, officers and employees in a form to be provided by the Company.

 

6.1           Recitals.
The parties agree that the Recitals set out herein are true and accurate and shall form part of this Agreement.

 

6.2           Headings.
The division of this Agreement into articles and sections and the insertion of headings are for the convenience of reference only
and shall not affect the construction or interpretation of this Agreement.

 

6.3           Assignment.
This Agreement shall be personal as to the Employee and shall not be assignable by the Employee subject to the terms herein. This
Agreement shall enure to the benefit of and be binding upon the heirs, executors, administrators and legal personal representatives
of the Employee and the successors and permitted assigns of the Company.

 

    	 

    	 

    

 

6.4           Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
cancels and supersedes any prior understandings and agreements between the parties hereto with respect thereto, whether verbal
or in writing. There are no other written or verbal representations, warranties, terms, conditions, undertakings or collateral
agreements, express, implied or statutory between the parties.

 

6.5           Amendments.
No amendment to this Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties hereto.
The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of
any subsequent breach by any party.

 

6.6           Severability.
If any provision of this Agreement is determined to be invalid or unenforceable in whole or in part, such invalidity or unenforceability
shall attach only to such provision or part thereof and the remaining part of such provision and all other provisions hereof shall
continue in full force and effect.

 

6.7           Further
Acts. The parties shall do all such further acts and things and provide all such assurances and deliver all such documents
in writing as may be required, from time to time in order to fully carry out the terms, provisions and intent of this Agreement.         

 

6.8           Notice.
Any demand, notice or other communication to be given in connection with this Agreement shall be given in writing by personal delivery,
electronic delivery or by registered mail addressed to the recipient as follows:

 

Bionik
Laboratories Inc.

 

10 Dundas Street
East, AMC-B202

 

Toronto, Ontario
M5B 2G9

 

Telephone:
(416) 574 4479 Email: info@bioniklabs.com

 

Peter Bloch

 

56 Wembley Rd,
Toronto, On M6C2G2

 

Tel #: (905)
339 - 9583

 

or such other address,
individual or telecopy number as may be designated by either party to the other in accordance herewith. Any notice given by personal
delivery will be conclusively deemed to have been given on the day of actual delivery of the notice and, if given by registered
mail, on the third day, other than a Saturday, Sunday or statutory holiday in Ontario, following the deposit of the notice in the
mail. If the party giving any notice knows or ought reasonably to know of any difficulties with the postal system that might affect
the delivery of mail, any such notice may not be mailed but must be given by personal delivery. In the case of electronic delivery,
on the same day that it was sent if sent on a business day and the acknowledgement of receipt is received by the sender before
5:00 p.m. (in the place of receipt) on such day, and otherwise on the first business day thereafter.

 

    	 

    	 

    

 

7.11         Jurisdiction.
This Agreement shall be governed by and construed in accordance with the laws of

 

the Province of Ontario
and any applicable federal laws of Canada. Each of the parties hereto agrees that any action or proceeding related to this Agreement
must be brought in any court of competent jurisdiction in the Province of Ontario, and for that purpose hereby attorns and submits
to the jurisdiction of such Ontario court.

 

6.9           Securities
Regulatory Authority Requirement. The Company and the Employee acknowledge

 

that this
Agreement shall be subject to compliance with any applicable rules, regulations and policies of any
stock exchange or exchanges on which any securities of the Company may from time to time be listed and any other securities authority
having jurisdiction.

 

6.10         Time
of the Essence. Time shall be of the essence in this Agreement.

 

6.11         Independent
Legal Advice. The Employee acknowledges that he has been advised to seek

 

independent legal counsel
in respect of the Agreement and the matters contemplated herein. To the extent that he declines to receive independent legal counsel
in respect of the Agreement, he waives the right, should a dispute later develop, to rely on his lack of independent legal counsel
to avoid his obligations, to seek indulgences from the Company or to otherwise attack the integrity of the Agreement and the provisions
thereof, in whole or in part.

 

IN WITNESS WHEREOF this
Agreement has been executed by the parties hereto as of the date first written above.

 

	SIGNED, SEALED AND DELIVERED	 	)	 
	in the presence of	 	 	 
	 	 	)	 
	 	 	)	 
	 	 	)	 
	 	 	)	 
	 	 	)	 
	/s/ 	 	)	 
	WITNESS	 	 	 

 

	 	BIONIK LABORATORIES INC.
	 	 
	 	Per:  	          /s/ Peter Bloch
	 	 	          Authorized Signing Officer
	 	
	 	I have authority to bind the corporation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]